Anti-PCSK9 Neutralizing Antibody

Catalog #: 71207
Size: 50 µg
Species: Human
Host Species: Freestyle 293 cells
MW: ~150 kDa
Tag(s): none
Clonality: Monoclonal (human)
Isotype: IgG1
PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
PCSK9 Neutralizing Antibody, a neutralizing recombinant human antibody (IgG1) recognizies the LDLR binding region of human PCSK9.
Assay Conditions:
3.8 ng/µl biotinylated PCSK9 was incubated with various concentrations of Anti-PCSK9 for 1 hr in a 50 µl reaction mix. Mixture was incubated on LDLR coated plate for 2 hr. Streptavidin labeled HRP was added and incubated for 1 hr. Finally, HRP chemiluminescent substrates were added and luminescence was read.
40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
LDLR binding region of human PCSK9
Aqueous buffer solution
Storage / Stability:

>6 months at -80°C.

Useful as an inhibitor of PCSK9-LDLR binding using the PCSK9[Biotinylated]-LDLR Binding Assay Kit, Cat. #72002.

1. Banerjee, Y., et al., N Engl J Med. 2012 Jun 21,366(25):2425-6.
2. Maxwell, K.N., Breslow, J.L., Circ Res. 2012 Jul 20,111(3):274-7.

Application Reference(s):
1. Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor (2017)
2. PCSK9 is a critical regulator of the innate immune response and septic shock outcome (2014)

Avoid freeze/thaw cycles
Scientific Category:
Product Type:
Data shown is lot-specific. Contact us for specific information on other lots.

Quality Assurance